Compare TSLX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | AUPH |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2014 | 1999 |
| Metric | TSLX | AUPH |
|---|---|---|
| Price | $19.23 | $14.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $23.50 | $17.25 |
| AVG Volume (30 Days) | 745.1K | ★ 836.9K |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | ★ 10.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.81 | 0.55 |
| Revenue | ★ $449,055,000.00 | $265,808,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | N/A | $16.45 |
| P/E Ratio | ★ $10.62 | $25.87 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $18.58 | $6.55 |
| 52 Week High | $25.17 | $16.54 |
| Indicator | TSLX | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 25.63 | 38.73 |
| Support Level | $19.63 | $14.21 |
| Resistance Level | $20.35 | $14.66 |
| Average True Range (ATR) | 0.59 | 0.45 |
| MACD | -0.21 | -0.02 |
| Stochastic Oscillator | 3.85 | 3.88 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.